ChroniSense Medical recently announced that it appointed Bridget Ross as chief executive officer, effective February 10.
“We are pleased Bridget will bring her talents to ChroniSense as CEO,” Ilan Neugarten, chairman of the board of Rainbow Medical and ChroniSense Medical’s largest investor, said in a news release. “We are confident Bridget’s extensive and diverse leadership experience will deliver impactful healthcare solutions to patients and will drive ChroniSense to a leading position in the disease management space.”
Ross has more than three decades of strategic, operational and leadership experience. Prior to joining the company, she was president of the global medical group at Henry Schein. She has also served in a number of leadership roles at Johnson & Johnson Medical Devices and in two of J&J’s women’s health and urology and otolaryngology subsidiaries.
“I am delighted to join ChroniSense,” Ross said. “The company’s breakthrough technology has the potential to be transformative for patients – a true game-changer in the digital health segment. I’m excited and honored to join the dedicated team at ChroniSense to work toward bringing meaningful benefits to patients, caregivers and shareholders alike.”
“We are excited about the potential for our technology to have an even greater impact on the lives of patients, and we are looking forward to a successful journey with Bridget’s leadership,” founder, president and director of ChroniSense Labs in Israel Danny Lange said.